abstract |
The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2- ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co- crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystelline forms, and salts, co-crystals, and pharmaceutical compositions thereof. |